ClinicalTrials.gg
Active, not recruitingNCT03519945Updated Apr 20, 2026

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

A Phase 3 interventional study of Mirikizumab in Ulcerative Colitis, sponsored by Eli Lilly and Company. Active, not recruiting at 352 sites in 36 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,058
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
3rd of 13
1,058 · median 172
Started
2018
with 2 others
Phase 3
7 of 13
1 open now
Registered
3rd of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 3rd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.

    • Female participants must agree to requirements.

Exclusion criteria

  • Participants must not have developed a new condition, including cancer in the originator study.

    • Participants must not have any important infections including, but not limited to, , , /AIDS, and active tuberculosis (TB) during either originator study
    • Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
    • Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,058 participants (actual)

Study arms

  • Experimental
    Mirikizumab

    Mirikizumab administered subcutaneously (SC).

    Drug: Mirikizumab

Interventions

  • Administered SC.

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission

    Clinical remission based on the modified Mayo Score (MMS).

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants in Endoscopic Remission

    Endoscopic remission based on the MMS Endoscopic Subscore (ES).

    Time frame: Week 52

  2. Percentage of Participants in Corticosteroid-free Remission

    Participants in corticosteroid-free remission.

    Time frame: Week 52

  3. Percentage of Participants with Histologic-Endoscopic Mucosal Remission at Week 52

    Endoscopic remission based on the MMS ES and histologic remission based on histologic disease activity index.

    Time frame: Week 52

  4. Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Score

    Health Related Quality of Life based on IBDQ score.

    Time frame: Baseline to Week 52

  5. UC Symptoms: Numeric Rating Score

    UC symptoms based on numeric rating score.

    Time frame: Week 160

  6. Percentage of Participants Who are Hospitalized Due to UC

    Participants who are hospitalized due to UC.

    Time frame: Baseline to Week 160

  7. Percentage of Participants Who Undergo UC Surgeries Including Colectomy

    Participants who undergo UC surgeries including colectomy.

    Time frame: Baseline to Week 160

07

Study locations

352 sites

Showing the first 100 of 352 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lee SD, Ehrlich AC, Pellanda P, Kaiser C, Todd K, Moses R, Walsh A. Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis. Am J Gastroenterol. 2025 Dec 1;120(12):2857-2866. doi: 10.14309/ajg.0000000000003407. Epub 2025 Mar 12. PubMed 40071779 ↗
  • Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. 2025 Jul 7;31(7):1876-1890. doi: 10.1093/ibd/izae253. PubMed 39448057 ↗

Individual participant data

Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Mar 2026, 91 months.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 91 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
May 9, 2018
StartActual
Jul 18, 2018
Primary completionActual
Mar 4, 2026
CompletionEst.
Dec 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03519945
Responsible party
Sponsor
First posted
May 9, 2018
Start date
Jul 18, 2018
Primary completion
Mar 4, 2026
Completion
Dec 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion